AIGH Capital Management LLC Makes New Investment in Day One Biopharmaceuticals, Inc. $DAWN

AIGH Capital Management LLC bought a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,520,492 shares of the company’s stock, valued at approximately $10,719,000. Day One Biopharmaceuticals accounts for 3.0% of AIGH Capital Management LLC’s portfolio, making the stock its 13th largest position. AIGH Capital Management LLC owned about 1.48% of Day One Biopharmaceuticals at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Royal Bank of Canada lifted its holdings in shares of Day One Biopharmaceuticals by 40.4% during the first quarter. Royal Bank of Canada now owns 185,733 shares of the company’s stock valued at $1,474,000 after purchasing an additional 53,459 shares during the last quarter. AQR Capital Management LLC increased its position in Day One Biopharmaceuticals by 601.4% during the 1st quarter. AQR Capital Management LLC now owns 618,627 shares of the company’s stock valued at $4,906,000 after buying an additional 530,429 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Day One Biopharmaceuticals by 6.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,992 shares of the company’s stock valued at $302,000 after buying an additional 2,149 shares during the last quarter. Millennium Management LLC boosted its holdings in Day One Biopharmaceuticals by 587.2% in the first quarter. Millennium Management LLC now owns 1,320,095 shares of the company’s stock worth $10,468,000 after acquiring an additional 1,127,995 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of Day One Biopharmaceuticals by 232.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,569,918 shares of the company’s stock worth $12,449,000 after acquiring an additional 1,097,679 shares during the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Insider Activity at Day One Biopharmaceuticals

In related news, insider Lauren Merendino sold 3,726 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $8.91, for a total transaction of $33,198.66. Following the sale, the insider owned 50,809 shares in the company, valued at approximately $452,708.19. This represents a 6.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Jeremy Bender sold 15,894 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $8.91, for a total transaction of $141,615.54. Following the completion of the sale, the chief executive officer directly owned 177,165 shares in the company, valued at approximately $1,578,540.15. This represents a 8.23% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 28,001 shares of company stock worth $249,489 in the last quarter. 6.20% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on DAWN shares. Zacks Research upgraded shares of Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 13th. JPMorgan Chase & Co. upped their target price on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Piper Sandler increased their price target on shares of Day One Biopharmaceuticals from $25.00 to $26.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, November 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $25.71.

Day One Biopharmaceuticals Price Performance

Shares of DAWN stock opened at $11.95 on Friday. The company has a market cap of $1.23 billion, a price-to-earnings ratio of -7.86 and a beta of -1.27. Day One Biopharmaceuticals, Inc. has a 1 year low of $5.64 and a 1 year high of $13.53. The firm has a fifty day moving average price of $9.36 and a 200-day moving average price of $7.98.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.09. The firm had revenue of $39.80 million for the quarter, compared to analysts’ expectations of $38.20 million. Day One Biopharmaceuticals had a negative return on equity of 32.05% and a negative net margin of 113.53%.The business’s quarterly revenue was down 57.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.38 EPS. Equities research analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.